RP MANAGEMENT, LLC other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/28/2024

Adviser Type:

- Large advisory firm

Number of Employees:

86 14.67%

of those in investment advisory functions:

43 38.71%

Registration:

SEC, Approved, 3/30/2012

AUM:

17,646,826,055 8.76%

of that, discretionary:

17,646,826,055 8.76%

GAV:

3,086,388,907 -3.49%

Avg Account Size:

928,780,319 8.76%

SMA’s:

NO

Private Funds:

4

Contact Info

212 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
19B 16B 13B 11B 8B 5B 3B
2015 2016 2017 2018 2019 2020 2021 2022 2023

Recent News

Miami Corp Management, LLC Buys
11/09/2021

Related Stocks: ^BVSP,

gurufocus.com

Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
04/01/2021

Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product ...

Yahoo Finance

Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
04/01/2021

Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when ...

Yahoo Finance

Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
04/01/2021

Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when ...

Yahoo Finance

Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
04/01/2021

Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product ...

Yahoo Finance

Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
04/01/2021

Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when ...

Yahoo Finance


Private Funds Structure

Fund Type Count GAV
Hedge Fund 1 $1,469,356,971
Private Equity Fund 3 $1,617,031,936

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
CLEARWATER MANAGEMENT CO., INC. 223.7m - 559.3m - - - - 782.9m 3.8b 8
ATLAS MERCHANT CAPITAL LLC 591.7m - 713.9m - - - - 1.3b 1.3b 7
SCHOOLCRAFT CAPITAL LLC 102.9m - 111.9m - - - - 214.8m 1.2b 9
STRATEGIC VALUE BANK PARTNERS LLC 211.5m - 236.5m - - - - 448.0m 559.3m 5
DAKOTA PACIFIC GLOBAL MACRO ADVISERS LP - - - - - - - - 447.9m -
BONAVENTURE CAPITAL, LLC 6.2m - 24.6m - - - - 30.8m 430.4m 4
HIGHLAND CAPITAL MANAGEMENT, L.P. 48.9m - 146.8m - - - - 195.7m 126.7m 4
MELKONIAN CAPITAL MANAGEMENT, LLC 306.5m - 65.7m - - - - 372.2m 372.2m 4
WALNUT GROVE CAPITAL PARTNERS, LP 47.6m - 124.9m - - - - 172.5m 172.5m 4
DIXON MIDLAND COMPANY LLC 63.7m - 20.9m - - - - 84.6m - 4

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
G1110E107 BIOHAVEN LTD $160,597,568 89.00% 28.00% 0.00%
09058V103 BIOCRYST PHARMACEUTICALS INC $19,538,462 11.00% -15.00% 0.00%
92765F108 VIRACTA THERAPEUTICS INC $3,774 0.00% 79.00% 0.00%

Brochure Summary

Overview

A. RP Management, LLC (also referred to as “we”, “us”, the “firm” and “RPM”), founded in 2003, is an investment services firm specializing in investment management for its clients. Its clients, including private funds and a public limited company incorporated under the laws of England and Wales (the “Clients”), indirectly own portions of subsidiaries holding royalty interests through their interests in one of three vehicles—(A) Royalty Pharma Select (“RPS”), an Irish Unit Trust, (B) Royalty Pharma Investments (“RPI”), an Irish Unit Trust (collectively with RPS, the “Unit Trusts”) or (C) Royalty Pharma Investments 2019 ICAV, an Irish Collective Asset-management Vehicle (the “ICAV”). The principal owner of our firm is Pablo Legorreta. Investors in our Clients are
referred to herein as “Investors”. B. RPM specializes in advising on investments in royalty interests in marketed and late stage developmental pharmaceutical, biopharmaceutical, medical and/or healthcare products. C. Our firm tailors our advisory services to the individual needs and specified investment mandates of our Clients. We adhere to the investment strategy set forth in the prospectuses of the Clients and the relevant investment management agreements. D. We do not participate in wrap fee programs. The amount of Client assets that we manage on a discretionary basis, as of December 31, 2022, measured in the same manner as our regulatory assets under management, was approximately $16,225,658,707. We do not manage any Client assets on a non-discretionary basis.